Literature DB >> 30992232

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.

Daniel R Reed1, Richard D Hall2, Ryan D Gentzler2, Leonid Volodin2, Michael G Douvas2, Craig A Portell2.   

Abstract

Entities:  

Keywords:  Cytogenics; Non-Hodgkin lymphoma; Peripheral T cell lymphoma; Targeted therapy; Treatment toxicity

Year:  2019        PMID： 30992232     DOI： 10.1016/j.clml.2019.03.001

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

1.  Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.

Authors:  Jing Yang; Jun Li; Wei-Yue Gu; Ling Jin; Yan-Long Duan; Shuang Huang; Meng Zhang; Xi-Si Wang; Yi Liu; Chun-Ju Zhou; Chao Gao; Hu-Yong Zheng; Yong-Hong Zhang
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Julian Verran; Vidya Mathavan
Journal:  Case Rep Hematol       Date:  2022-02-03

3.  Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

Authors:  Ritsuko Nakai; Suguru Fukuhara; Akiko Miyagi Maeshima; Sung-Won Kim; Yuta Ito; Shunsuke Hatta; Tomotaka Suzuki; Sayako Yuda; Shinichi Makita; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Koji Izutsu
Journal:  Clin Case Rep       Date:  2019-11-15

4.  Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies.

Authors:  Enass H Raffa; Helen M Branson; Bo Ngan; Sarah Alexander; Oussama Abla
Journal:  Cancer Rep (Hoboken)       Date:  2021-04-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.